Companies do M&A deals for all sorts of reasons. Biogen bought Apellis for $5.6 billion in March mainly for its approved rare disease drug Empaveli, and has now halted or cancelled development of most of the pipeline products it got through the deal. Kyle LaHucik has the details here.